User:Brian Hernandez/DOPA Decarboxylase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 24: Line 24:
==='''Inhibitor Binding'''===
==='''Inhibitor Binding'''===
The inhibitor '''carbiDOPA''' binds to the enzyme by forming a hydrazone linkage with the PLP cofactor through its hydrazine moiety <ref name=Burkhard>PMID: 11685243 </ref>.
The inhibitor '''carbiDOPA''' binds to the enzyme by forming a hydrazone linkage with the PLP cofactor through its hydrazine moiety <ref name=Burkhard>PMID: 11685243 </ref>.
 +
[[Image:carbidopa.jpeg]]

Revision as of 05:21, 29 November 2011

DDC in complex with carbiDOPA (PDB entry 1js3)

Drag the structure with the mouse to rotate


DDC and Parkinson's Disease

Treatment

Parkinson's disease, a neurological disorder, can be characterized by tremor, bradykinesia, rigidity, and postural instability. With it's possible relation to degenerative dopamine-producing cells in the brain, administration of L-DOPA can increase the amount of synthesized dopamine in the nerve cell; direct treatment with dopamine is not sufficient as dopamine itself cannot pass the blood-brain barrier. However, only a small percentage of the dose actually reaches the nervous system, with the remaining majority being rapidly converted to dopamine in the blood stream. This dopamine-rich blood causes side effects of nausea, daytime sleepiness, orthostatic hypotension, involuntary movements, decreased appetite, insomnia, and cramping. Addition of a DDC inhibitor would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and diminishing the side effects of dopamine-rich blood.

Inhibitor Binding

The inhibitor carbiDOPA binds to the enzyme by forming a hydrazone linkage with the PLP cofactor through its hydrazine moiety [1]. Image:carbidopa.jpeg

Proteopedia Page Contributors and Editors (what is this?)

Brian Hernandez

Personal tools